Stockreport
Mirum Pharmaceuticals Appoints Peter Radovich as Chief Operating Officer
Last mirum pharmaceuticals, inc. - common stock earnings: 3/12 04:02 pm
Check Earnings Report
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases, today announced the appointment of Peter Radovich as its chief operating officer with oversight of commercial operations, technical operations, supply chain and corporate development. Mr. Radovich joins Mirum with nearly 20 years leading biopharmaceutical development and commercialization programs, having served most recently as executive vice president, operations for South San Francisco-based Global Blood Therapeutics.“I am thrilled to welcome Peter to Mirum and look forward to working together to deliver new treatments to patients with rare liver diseases,” said Chris Peetz, president and chief executive officer, Mirum. “Peter is an effective leader and brings a patient-first mentality fitting with the Mirum strategy. His extensive experience lau
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | MIRM | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
MIRM alerts
MIRM alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
MIRM alerts
High impacting Mirum Pharmaceuticals, Inc. - common stock news events
Weekly update
A roundup of the hottest topics
MIRM
NEWS
NEWS
- Mirum Pharmaceuticals (NASDAQ:MIRM) was upgraded by analysts at Royal Bank Of Canada to a "moderate buy" rating.[MarketBeat]
- Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2025 Financial Results and Host Conference Call on February 25, 2026 [Yahoo! Finance][Yahoo! Finance]
- Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2025 Financial Results and Host Conference Call on February 25, 2026[Business Wire]
- Mirum Pharmaceuticals (NASDAQ:MIRM) was given a new $130.00 price target on by analysts at Royal Bank Of Canada. They now have an "outperform" rating on the stock.[MarketBeat]
- Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)[Business Wire]
- More
MIRM
SEC Filings
SEC Filings
- 2/17/26 - Form 4
- 2/17/26 - Form SCHEDULE
- 2/13/26 - Form 144
- MIRM's page on the SEC website
- More